Andere Sprachen Aadi Bioscience, Inc.

Aktien

A3CSR9

US00032Q1040

AADI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
1,78 ^USD	-3,26 %		-2,20 %	-11,88 %

13.03.	Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024
13.03.	Aadi Bioscience, Inc. meldet Ergebnis für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research Annual Meeting	10.04.
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)	17.03.
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M	13.03.
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13.03.
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update	13.03.
North American Morning Briefing : Stock Futures -2-	13.03.
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update	06.03.
North American Morning Briefing : Stock Futures Hover At Start of Busy Week	04.03.
Aadi Bioscience Reports Supportive Data from Tumor Treatment Trial -- Shares Jump After Hours	01.03.
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa	01.03.
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference	26.02.
North American Morning Briefing : Stock Futures -2-	18.12.
Sector Update: Health Care Stocks Retreating Late Afternoon	15.12.
Top Midday Decliners	15.12.
Wall Street Set to Open Narrowly Mixed Ahead of PMI, Industrial Production Data	15.12.
Top Premarket Decliners	15.12.
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations	14.12.
Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations	14.12.
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $6M	08.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aadi Bioscience, Inc.

Aktien

A3CSR9

US00032Q1040

AADI

Andere Sprachen

Filter